Mar. 29 at 4:18 PM
$PMCB For diabetes, PharmaCyte is exploring the use of Cell-in-a-Box to encapsulate insulin-producing cells (such as genetically modified human liver cells or stem cells) to create a "bio-artificial pancreas." Once implanted, these cells could produce and release insulin in response to blood sugar levels, offering a potential long-term solution for insulin-dependent diabete.The company has a research agreement with the University of Technology, Sydney, to develop this approach using Melligen cells, a genetically engineered cell line.
As of March 29, 2025, PharmaCyte Biotech (
$PMCB) is listed on NASDAQ with a market capitalization of around
$12.9 million, reflecting its status as a small-cap biotech. Historically, the company has experienced volatile stock performance, with significant price swings in the past (e.g., reaching
$0.60 in 2014 but trading much lower in recent years). Its financial position has included substantial cash reserves—reported at
$74.6 million.
